

Curriculum Vitae

Date: 1/6/17

A. Identifying data:

Name: Gregory Mark Enns, M.B., Ch.B.
Ethnicity: Caucasian
Citizenship: United States of America
Licensure: California #A52095
Hawaii #MD12592
United Kingdom #3469202

B. Academic History:

Undergraduate: B.A., Biology: May, 1984
Pomona College
Pomona, CA
August, 1980–May, 1984

Graduate: Diploma, Medical Science: June, 1987
University of St. Andrews
St. Andrews, Scotland
September, 1985–June, 1987

M.B., Ch.B.: June, 1990
University of Glasgow
Glasgow, Scotland
September, 1987–June, 1990

Honors and Awards: Kellogg Foundation Scholarship, UC Davis, 1984
P.T. Herring Memorial Prize in Histology, University of St. Andrews, 1986
First Class Merit Certificates: Anatomy, Physiology, Biochemistry, General Pathology, Microbiology, and Pharmacology, University of St. Andrews, 1985-87
Neil Arnott Memorial Prize in Clinical Physics, University of Glasgow, 1988
University of Glasgow Clinical Travel Grant, for clinical studies in China and Nepal, 1988
C.H.L.A. Board of Directors Award for outstanding service as Pediatric Chief Resident, 1995
U.C.S.F. Liver Center Pilot/Feasibility Grant for Hepatic Gene Therapy Research, 1998
Pete and Arline Harman Scholarship, 2005

Horizon Exhibit 2007

Stanford University School of Medicine Honor Roll for Teaching,
2005-2006
Distinguished Service Citation, American Academy of Pediatrics,
2011
Outstanding Service Citation, United Mitochondrial Disease
Foundation, 2011
Stanford University School of Medicine Excellence in Teaching
Citation, 2011–2012
PCARES Rose Award, Lucile Packard Children's Hospital, 2015

Post-Graduate Training: Junior House Officer, Pediatric Surgery
Royal Hospital for Sick Children, Yorkhill
Glasgow, Scotland
August, 1990–January, 1991

Junior House Officer, General Medicine
Glasgow Royal Infirmary
Glasgow, Scotland
January, 1991–June, 1991

Intern and Resident, Pediatrics
Children's Hospital of Los Angeles
Los Angeles, California
June, 1991–June, 1994

Chief Resident, Pediatrics
Children's Hospital of Los Angeles
Los Angeles, California
June, 1994–June, 1995

Fellow, Medical Genetics
University of California, San Francisco
San Francisco, California
June, 1995 – June, 1998

Board Certification: American Board of Pediatrics (10/12/94, 6/14/01, 11/06/08)
American Board of Medical Genetics, Diplomate, Clinical Genetics
(9/1/99, 1/1/10)
American Board of Medical Genetics, Diplomate, Clinical
Biochemical Genetics (9/1/99, 1/1/10)
ECFMG 0-447-053-0

Research/Contract
Support:

RP103-MITO-001 (Enns)	10/08/14–09/30/16	3.18 CM
Raptor Pharmaceuticals		\$254,794
An Open-label, Dose-Escalating Study to Assess the Safety, Tolerability and Efficacy of Cysteamine Bitratrate Delayed-release capsules (RP103) for the Treatment of Children with Inherited Mitochondrial Disease		
<i>This is an open-label study focusing on the safety and preliminary efficacy of cysteamine bitatartrate to treat patients with Leigh syndrome and other inherited mitochondrial disorders.</i>		
RP103-MITO-002 (Enns)	07/20/15–05/31/17	1.66 CM
Raptor Pharmaceuticals		\$359,162
A Long-Term Open-Label Extension Study of RP103-MITO-001 to Assess the Safety, Tolerability and Efficacy of Cysteamine Bitratrate Delayed-release capsules (RP103) for the Treatment of Children with Inherited Mitochondrial Disease		
<i>This is an extension study for the RP103 protocol, a study using cysteamine bitartrate to treat patients with Leigh syndrome and other inherited mitochondrial disorders.</i>		
IND#107,401 (Enns)	12/09/13 – 11/30/16	0.56 CM
Edison Pharmaceuticals		\$224,765
Long-Term Safety and Efficacy Evaluation of EPI-743 in Children with Leigh Syndrome		
<i>This is a long-term follow-up study to the Phase 2B randomized clinical trial in Leigh syndrome, the first randomized trial using a novel redox-modulating agent to treat mitochondrial disease.</i>		
EPI743 (Enns)	08/20/10–04/14/16	0.12 CM
Emergency Use Protocol for EPI-743 in Acutely Ill Patients with Inherited Mitochondrial Respiratory Chain Disease Within 90 Days of End-of-life Care		
<i>This is an emergency treatment protocol for mitochondrial disease patients using a novel redox-modulating agent.</i>		
SPO117002 (Enns)	04/01/15 – 03/31/16	0.24 CM
National Institutes of Health		
Lumina Diagnostics, Inc.		
Breath Ammonia Monitoring Device for Children with Urea Cycle Disorders		
<i>The goal of this project is to develop a novel breath sensor to measure ammonia in patients with urea cycle disorders.</i>		

1R01DK1028201A1 (Peltz) 01/01/15–12/31/17 0.60 CM
National Institutes of Health \$382,029
Stem Cell-Based In vivo Models of Human Genetic Liver Diseases
The goal of this grant is to generate murine models of genetic liver diseases, including polymerase gamma deficiency and Alagille syndrome, using stem cell techniques to generate “humanized” liver tissue.

Data and Website (Enns) 07/01/09–06/30/16 0.12 CM
Genzyme Corporation \$63,885
Gaucher, Fabry, MPS 1 and other Genetically Based Metabolic Disorders
This is a longitudinal registry program for lysosomal storage disorders.

LAL-CL02 (Enns) 05/31/13–03/31/17 0.60 CM
Synageva BioPharma Corp. \$406,690
A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients with Lysosomal Acid Lipase Deficiency.
This is a clinical trial using a novel enzyme replacement therapy to treat LAL deficiency.

GOS (Enns) 09/16/11–08/31/18 0.12 CM
Shire Human Genetics Therapies, Inc. \$126,201
Gaucher Disease Outcome Survey (GOS)
This is a longitudinal registry program for Gaucher Disease.

NIH 14-GG006326 (Enns) 09/01/13–08/31/18 0.01 CM
North American Mitochondrial Disease Consortium \$580
This is a registry program for mitochondrial disease patients.

Foundation Grant (Enns) 06/01/14–03/31/16 0.12 CM
Austin Memorial Foundation \$45,873
A cell-based method for screening mitochondrial disease therapies.
This study focuses on the use of spectromicroscopy and tandem mass spectrometry to study fibroblasts obtained from mitochondrial disease patients.

C. Employment History:

Academic Appointments: Clinical Instructor, Pediatrics
University of Southern California
June, 1994–June, 1995

Clinical Instructor, Pediatrics
University of California, San Francisco
July, 1998–present

Assistant Professor of Pediatrics
Stanford University
October, 1998–October, 2006

Associate Professor of Pediatrics
Stanford University
November, 2006–May, 2015

Professor of Pediatrics
Stanford University
June, 2015–present

Administrative
Appointments:

Director, Biochemical Genetics Program
Stanford University School of Medicine
October, 1998–present

Scientific Advisory Board, Genotyping Core
Stanford University School of Medicine
May, 2000–June, 2001

Co-Director, UCSF/Stanford Lysosomal Disease Center
Stanford University Medical Center
July, 2000–present

Director, Metabolic Special Care Center
Lucile Salter Packard Children's Hospital
June, 2001–present

Medical Consultant, Newborn Screening Area Service Center
Stanford University Medical Center
June 2003–present

Program Director, Medical Genetics Residency Training Program
Stanford University School of Medicine
September, 2007–April, 2013

Associate Program Director, Medical Genetics Residency Training
Program
Stanford University School of Medicine
May, 2013–April, 2014

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.